世界の人間生体機能チップ市場は、2025年に221百万米ドルと算定されており、2026年には281百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）30.2%で推移し、2032年には1368百万米ドルに達すると予測されています。

本レポートは、人間生体機能チップメーカー、新規参入企業、および業界バリューチェーン全体の企業に対し、市場全体およびサブセグメント別の収益、生産量、平均価格に関する情報を、企業別、タイプ別、用途別、地域別に提供します。
世界の人間生体機能チップ市場について、定量的・定性的分析を交えた包括的な概観を提供し、企業関係者が成長戦略の策定、競争環境の評価、現行市場における自社の位置付けの分析、人間生体機能チップに関する情報に基づいたビジネス判断を行うことを支援します。人間生体機能チップ市場の規模、推定値及び予測値の観点から提示し、2025年を基準年として、2021年から2032年までの過去データ及び予測データを収録しております。

報告対象範囲
売上高・数量予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
Emulate
MIMETAS
TissUse
CN Bio Innovations
AIM Biotech
AlveoliX
Beonchip
React4life
InSphero
NETRI
SynVivo
BiomimX
Dynamic42
Kirkstall
Cherry Biotech
Micronit
Cellbox Labs
REVIVO BioSystems
MesoBioTech
Beijing Daxiang Biotech
AVATARGET
Suzhou Jiyan Biopharmaceutical


タイプ別
Brain-on-a-chip
Liver-on-a-chip
Kidney-on-a-chip
Lung-on-a-chip
Heart-on-a-chip
Intestine-on-a-chip
Vessel-on-a-chip
Other Organs


用途別
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Cosmetics Industry
Others


製品カテゴリー


市場セグメント
Membrane-based Organ-on-Chip
Membrane-free Organ-on-Chip

地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
本レポートは、世界の人間生体機能チップ市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、企業別の市場規模も提供されます。より深い洞察を得るため、競争環境、主要競合他社、それぞれの市場順位をプロファイリングし、技術動向や新製品開発についても論じております。

本レポートの構成
第1章：人間生体機能チップの定義および調査範囲を明確化し、市場セグメント（タイプ別、用途別など）の概要を提示します。各セグメントの市場規模と将来の成長可能性を網羅し、現在の市場状況の概要を提供するとともに、短期・中期・長期の発展トレンドを分析します
第2章：人間生体機能チップメーカーの競争環境について、価格、生産量、価値ベースの市場シェア、最新の開発計画、合併・買収情報を含め詳細に分析します
第3章：人間生体機能チップの生産量／生産高および価値を地域・国別に検証し、今後6年間の各地域の市場規模と成長可能性について定量的な評価を提供します
第4章：地域および国レベルでの人間生体機能チップの消費動向を分析します。各地域および主要国における市場規模と成長可能性を定量化し、市場開発状況、見通し、対応可能な市場規模、国内生産量を概説します
第5章：人間生体機能チップに基づくタイプ別市場セグメントの構造を整理し、各セグメントの市場規模と成長ポテンシャルを明確化することで、企業・投資家によるブルーオーシャン機会の発見を支援します
第6章：用途別に人間生体機能チップの市場セグメントを整理し、各分野の市場規模、成長ポテンシャル、需要拡大余地を提示することで、下流市場における有望な参入機会や競争優位の確立に向けた判断材料を提供します
第7章：人間生体機能チップの主要プレイヤーを分析し、主要企業の基本情報（製品生産量／生産高、価値、価格、粗利益率、製品ポートフォリオ／新製品導入、最近の動向）を詳細に説明します
第8章：人間生体機能チップの上流および下流セグメントを含む業界バリューチェーンをレビューします
第9章：人間生体機能チップ市場の動向と最新トレンドについて議論します。これには、メーカーにとっての推進要因、制約要因、課題、リスク、米国関税、関連政策分析が含まれます
第10章：主な調査結果と結論をまとめます
第11章：付録

The global Organ On Chip market was valued at US$ 221 million in 2025 and is anticipated to reach US$ 1368 million by 2032, at a CAGR of 30.2% from 2026 to 2032.

A Organ on Chip is a small-scale device that replicates the mechanical and biological properties of human organs. These chips contain tiny channels lined with living human cells that form tissue layers. They can simulate the physiology of various organs, such as the heart, liver, lungs, kidneys, and intestines, allowing researchers to better understand organ-specific functions and diseases. These models are typically made using microfluidic technology, where human cells are cultured in a small, transparent chip, allowing researchers to simulate organ-specific functions and study disease processes, drug responses, and more. By offering more accurate, scalable, and human-relevant data, Human Organs-on-Chips are revolutionizing biomedical research and drug testing, providing a bridge between traditional animal models and human clinical trials.The price of Organ-on-Chip products varies significantly depending on chip architecture, number of microfluidic channels, integration of perfusion or sensing functions, and automation level. In 2025–2026, basic microfluidic organ-on-chip devices are generally priced at around US$20–100 per chip, while multi-well or high-throughput chip plates are typically about US$80–500 per plate. Supporting pumps, controllers, and culture modules usually cost approximately US$3,000–20,000 per system, while fully integrated and automated organ-on-chip platforms may exceed US$20,000–100,000 per system.

The upstream value chain mainly includes chip substrate materials such as PDMS, COP/COC, and glass, together with porous membranes, ECM/hydrogels, cells, culture media, sensors, and microfluidic components. Midstream companies such as Emulate, MIMETAS, TissUse, CN Bio, and AIM Biotech are responsible for microfluidic chip design, manufacturing, and integration of culture and perfusion systems. Downstream users mainly include pharmaceutical and biotechnology companies, CROs, academic and research institutions, and regulatory science organizations. Organ-on-chip platforms are primarily used for drug screening, ADME/DMPK studies, toxicology assessment, disease modeling, precision medicine, and the reduction or replacement of animal testing.

Market Drivers
Regulatory Support for Reducing Animal Testing
Global drug development regulations are increasingly encouraging the adoption of non-animal testing methods. Organ-on-chip systems can use human-derived cells to reproduce organ-specific microenvironments and physiological functions, offering stronger human relevance for drug safety, toxicology, and efficacy assessment. Continued support from regulatory and research organizations such as the FDA, NIH, and European institutions is accelerating the adoption and commercialization of microphysiological systems and organ-on-chip technologies.

Growing Demand to Improve Pharmaceutical R&D Efficiency
Traditional two-dimensional cell cultures and animal models have limitations in predicting human drug responses. Organ-on-chip platforms combine three-dimensional cell culture, microfluidics, dynamic perfusion, and multicellular co-culture to better reproduce human tissue environments. As drug development costs continue to rise, pharmaceutical companies are increasingly using organ-on-chip systems for candidate screening, ADME/DMPK studies, toxicity testing, and disease modeling.

Increasing Demand for Precision Medicine and Human-Relevant Disease Models
Organ-on-chip technologies can be integrated with patient-derived cells, induced pluripotent stem cells, organoids, and gene-editing technologies to create human-relevant models with specific genetic and disease characteristics. Growing demand for precision treatment in oncology, neurological disorders, rare diseases, and metabolic diseases is expanding the application of organ-on-chip systems in personalized drug screening, disease mechanism research, and patient stratification.

Market Restraints
Relatively High Equipment and Experimental Costs
Organ-on-chip experiments often require microfluidic chips, specialized culture media, extracellular matrices, hydrogels, pumping systems, sensors, and imaging equipment. Overall experimental costs are generally higher than conventional two-dimensional cell culture and standard microplate assays. Integrated and automated organ-on-chip platforms also require relatively high initial capital investment, which can limit adoption among small laboratories and research institutions with restricted budgets.

Limited Standardization Across Platforms
Organ-on-chip manufacturers use different chip materials, channel geometries, membranes, cell sources, culture conditions, flow rates, and analytical methods. The industry has not yet established fully standardized technical specifications and evaluation systems. Differences among platforms may reduce inter-laboratory reproducibility and data comparability, creating barriers to broader adoption in standardized pharmaceutical development and regulatory assessment.

Constraints in High-Quality Cell Sources and Long-Term Culture
The performance of organ-on-chip systems strongly depends on the quality of primary cells, stem-cell-derived cells, and other human-derived biological materials. Some organ-specific cell types remain difficult to obtain and may exhibit batch-to-batch variability, phenotype instability, or limited long-term viability. Variability in cellular materials can directly affect experimental consistency and complicate large-scale deployment and standardized validation.Market Opportunities
Expanding Applications in Drug Safety and Toxicology Assessment
Organ-on-chip platforms have significant potential in drug-induced liver injury, cardiotoxicity, nephrotoxicity, pulmonary toxicity, and blood-brain barrier studies. As regulatory authorities gradually increase acceptance of human-relevant alternative models, organ-on-chip systems are expected to move beyond academic research and become increasingly integrated into preclinical safety assessment workflows, creating strong opportunities for liver-on-chip, heart-on-chip, kidney-on-chip, and related platforms.

Development of High-Throughput and Automated Platforms
The industry is moving from individual microfluidic devices toward multi-well-compatible, high-throughput, and automated systems. These platforms are increasingly integrated with automated liquid handling, high-content imaging, real-time biosensors, and AI-based data analysis. High-throughput systems can reduce per-test costs, improve reproducibility, and facilitate integration into existing pharmaceutical screening workflows, supporting growth in both consumable chips and supporting instruments.

Strong Potential for Multi-Organ and Body-on-Chip Systems
Multi-organ platforms can connect liver, intestine, kidney, heart, and other tissue models to investigate drug absorption, distribution, metabolism, excretion, and organ-to-organ interactions. As microfluidic control, long-term culture, and multi-organ coupling technologies continue to improve, these systems are expected to gain wider use in systemic toxicology, PK/PD analysis, and complex disease modeling, creating new high-value market segments.

Market Challenges
Balancing Physiological Relevance with Throughput
Organ-on-chip systems rely on multicellular co-culture, three-dimensional extracellular matrices, mechanical stimulation, dynamic fluid flow, and sensing technologies to improve physiological relevance. However, greater biological complexity generally increases manufacturing costs, operational difficulty, and experimental failure risks. Achieving an effective balance among model complexity, reproducibility, throughput, cost, and ease of use remains a major technical challenge for large-scale commercialization.

Regulatory Acceptance Requires Extensive Validation
Although regulatory authorities are showing increasing interest in organ-on-chip and microphysiological systems, replacing conventional animal testing or using these platforms for formal regulatory decision-making still requires extensive inter-laboratory validation, reference-compound testing, and comparison with clinical data. Different organ models may progress through validation and regulatory acceptance at different speeds, potentially slowing commercial adoption.

Competition Among Multiple Technology Platforms
The market includes membrane-based, membrane-free, ECM-based microfluidic, multi-well plate, pump-driven, and gravity-driven organ-on-chip architectures. Each platform has different advantages in physiological relevance, throughput, operational complexity, and cost. Uncertainty over which technologies will ultimately become widely accepted by pharmaceutical companies and regulatory authorities increases R&D risks for manufacturers and platform-selection risks for customers.

Report Scope
This report delivers a comprehensive overview of the global Organ On Chip market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Organ On Chip. The Organ On Chip market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Organ On Chip market comprehensively. Regional market sizes by Type, by End User, by System Integration, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Organ On Chip manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by End User, and by region.

Market Segmentation
By Company
Emulate
MIMETAS
TissUse
CN Bio Innovations
AIM Biotech
AlveoliX
Beonchip
React4life
InSphero
NETRI
SynVivo
BiomimX
Dynamic42
Kirkstall
Cherry Biotech
Micronit
Cellbox Labs
REVIVO BioSystems
MesoBioTech
Beijing Daxiang Biotech
AVATARGET
Suzhou Jiyan Biopharmaceutical

Segment by Type
Brain-on-a-chip
Liver-on-a-chip
Kidney-on-a-chip
Lung-on-a-chip
Heart-on-a-chip
Intestine-on-a-chip
Vessel-on-a-chip
Other Organs

Segment by System Integration
Single-organ-on-Chip
Multi-organ-on-Chip

Segment by Chip Structure
Membrane-based Organ-on-Chip
Membrane-free Organ-on-Chip

Segment by End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Cosmetics Industry
Others

By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by End User, by System Integration, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Organ On Chip companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by End User, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Organ On Chip Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Brain-on-a-chip
1.2.3 Liver-on-a-chip
1.2.4 Kidney-on-a-chip
1.2.5 Lung-on-a-chip
1.2.6 Heart-on-a-chip
1.2.7 Intestine-on-a-chip
1.2.8 Vessel-on-a-chip
1.2.9 Other Organs
1.3 Market by System Integration
1.3.1 Global Organ On Chip Market Size Growth Rate by System Integration: 2021 vs 2025 vs 2032
1.3.2 Single-organ-on-Chip
1.3.3 Multi-organ-on-Chip
1.4 Market by Chip Structure
1.4.1 Global Organ On Chip Market Size Growth Rate by Chip Structure: 2021 vs 2025 vs 2032
1.4.2 Membrane-based Organ-on-Chip
1.4.3 Membrane-free Organ-on-Chip
1.5 Market by End User
1.5.1 Global Organ On Chip Market Growth by End User: 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical & Biotechnology Companies
1.5.3 Academic & Research Institutes
1.5.4 Cosmetics Industry
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends
2.1 Global Organ On Chip Market Perspective (2021–2032)
2.2 Global Organ On Chip Growth Trends by Region
2.2.1 Global Organ On Chip Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Organ On Chip Historic Market Size by Region (2021–2026)
2.2.3 Organ On Chip Forecasted Market Size by Region (2027–2032)
2.3 Organ On Chip Market Dynamics
2.3.1 Organ On Chip Industry Trends
2.3.2 Organ On Chip Market Drivers
2.3.3 Organ On Chip Market Challenges
2.3.4 Organ On Chip Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Organ On Chip Players by Revenue
3.1.1 Global Top Organ On Chip Players by Revenue (2021–2026)
3.1.2 Global Organ On Chip Revenue Market Share by Players (2021–2026)
3.2 Global Top Organ On Chip Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Organ On Chip Revenue
3.4 Global Organ On Chip Market Concentration Ratio
3.4.1 Global Organ On Chip Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Organ On Chip Revenue in 2025
3.5 Global Key Players of Organ On Chip Head Offices and Areas Served
3.6 Global Key Players of Organ On Chip, Products and Applications
3.7 Global Key Players of Organ On Chip, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans

4 Organ On Chip Breakdown Data by Type
4.1 Global Organ On Chip Historic Market Size by Type (2021–2026)
4.2 Global Organ On Chip Forecasted Market Size by Type (2027–2032)

5 Organ On Chip Breakdown Data by End User
5.1 Global Organ On Chip Historic Market Size by End User (2021–2026)
5.2 Global Organ On Chip Forecasted Market Size by End User (2027–2032)

6 North America
6.1 North America Organ On Chip Market Size (2021–2032)
6.2 North America Organ On Chip Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Organ On Chip Market Size by Country (2021–2026)
6.4 North America Organ On Chip Market Size by Country (2027–2032)
6.5 United States
6.6 Canada

7 Europe
7.1 Europe Organ On Chip Market Size (2021–2032)
7.2 Europe Organ On Chip Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Organ On Chip Market Size by Country (2021–2026)
7.4 Europe Organ On Chip Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland

8 Asia-Pacific
8.1 Asia-Pacific Organ On Chip Market Size (2021–2032)
8.2 Asia-Pacific Organ On Chip Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Organ On Chip Market Size by Region (2021–2026)
8.4 Asia-Pacific Organ On Chip Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand

9 Latin America
9.1 Latin America Organ On Chip Market Size (2021–2032)
9.2 Latin America Organ On Chip Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Organ On Chip Market Size by Country (2021–2026)
9.4 Latin America Organ On Chip Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Organ On Chip Market Size (2021–2032)
10.2 Middle East & Africa Organ On Chip Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Organ On Chip Market Size by Country (2021–2026)
10.4 Middle East & Africa Organ On Chip Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE

11 Key Players Profiles
11.1 Emulate
11.1.1 Emulate Company Details
11.1.2 Emulate Business Overview
11.1.3 Emulate Organ On Chip Introduction
11.1.4 Emulate Revenue in Organ On Chip Business (2021–2026)
11.1.5 Emulate Recent Development
11.2 MIMETAS
11.2.1 MIMETAS Company Details
11.2.2 MIMETAS Business Overview
11.2.3 MIMETAS Organ On Chip Introduction
11.2.4 MIMETAS Revenue in Organ On Chip Business (2021–2026)
11.2.5 MIMETAS Recent Development
11.3 TissUse
11.3.1 TissUse Company Details
11.3.2 TissUse Business Overview
11.3.3 TissUse Organ On Chip Introduction
11.3.4 TissUse Revenue in Organ On Chip Business (2021–2026)
11.3.5 TissUse Recent Development
11.4 CN Bio Innovations
11.4.1 CN Bio Innovations Company Details
11.4.2 CN Bio Innovations Business Overview
11.4.3 CN Bio Innovations Organ On Chip Introduction
11.4.4 CN Bio Innovations Revenue in Organ On Chip Business (2021–2026)
11.4.5 CN Bio Innovations Recent Development
11.5 AIM Biotech
11.5.1 AIM Biotech Company Details
11.5.2 AIM Biotech Business Overview
11.5.3 AIM Biotech Organ On Chip Introduction
11.5.4 AIM Biotech Revenue in Organ On Chip Business (2021–2026)
11.5.5 AIM Biotech Recent Development
11.6 AlveoliX
11.6.1 AlveoliX Company Details
11.6.2 AlveoliX Business Overview
11.6.3 AlveoliX Organ On Chip Introduction
11.6.4 AlveoliX Revenue in Organ On Chip Business (2021–2026)
11.6.5 AlveoliX Recent Development
11.7 Beonchip
11.7.1 Beonchip Company Details
11.7.2 Beonchip Business Overview
11.7.3 Beonchip Organ On Chip Introduction
11.7.4 Beonchip Revenue in Organ On Chip Business (2021–2026)
11.7.5 Beonchip Recent Development
11.8 React4life
11.8.1 React4life Company Details
11.8.2 React4life Business Overview
11.8.3 React4life Organ On Chip Introduction
11.8.4 React4life Revenue in Organ On Chip Business (2021–2026)
11.8.5 React4life Recent Development
11.9 InSphero
11.9.1 InSphero Company Details
11.9.2 InSphero Business Overview
11.9.3 InSphero Organ On Chip Introduction
11.9.4 InSphero Revenue in Organ On Chip Business (2021–2026)
11.9.5 InSphero Recent Development
11.10 NETRI
11.10.1 NETRI Company Details
11.10.2 NETRI Business Overview
11.10.3 NETRI Organ On Chip Introduction
11.10.4 NETRI Revenue in Organ On Chip Business (2021–2026)
11.10.5 NETRI Recent Development
11.11 SynVivo
11.11.1 SynVivo Company Details
11.11.2 SynVivo Business Overview
11.11.3 SynVivo Organ On Chip Introduction
11.11.4 SynVivo Revenue in Organ On Chip Business (2021–2026)
11.11.5 SynVivo Recent Development
11.12 BiomimX
11.12.1 BiomimX Company Details
11.12.2 BiomimX Business Overview
11.12.3 BiomimX Organ On Chip Introduction
11.12.4 BiomimX Revenue in Organ On Chip Business (2021–2026)
11.12.5 BiomimX Recent Development
11.13 Dynamic42
11.13.1 Dynamic42 Company Details
11.13.2 Dynamic42 Business Overview
11.13.3 Dynamic42 Organ On Chip Introduction
11.13.4 Dynamic42 Revenue in Organ On Chip Business (2021–2026)
11.13.5 Dynamic42 Recent Development
11.14 Kirkstall
11.14.1 Kirkstall Company Details
11.14.2 Kirkstall Business Overview
11.14.3 Kirkstall Organ On Chip Introduction
11.14.4 Kirkstall Revenue in Organ On Chip Business (2021–2026)
11.14.5 Kirkstall Recent Development
11.15 Cherry Biotech
11.15.1 Cherry Biotech Company Details
11.15.2 Cherry Biotech Business Overview
11.15.3 Cherry Biotech Organ On Chip Introduction
11.15.4 Cherry Biotech Revenue in Organ On Chip Business (2021–2026)
11.15.5 Cherry Biotech Recent Development
11.16 Micronit
11.16.1 Micronit Company Details
11.16.2 Micronit Business Overview
11.16.3 Micronit Organ On Chip Introduction
11.16.4 Micronit Revenue in Organ On Chip Business (2021–2026)
11.16.5 Micronit Recent Development
11.17 Cellbox Labs
11.17.1 Cellbox Labs Company Details
11.17.2 Cellbox Labs Business Overview
11.17.3 Cellbox Labs Organ On Chip Introduction
11.17.4 Cellbox Labs Revenue in Organ On Chip Business (2021–2026)
11.17.5 Cellbox Labs Recent Development
11.18 REVIVO BioSystems
11.18.1 REVIVO BioSystems Company Details
11.18.2 REVIVO BioSystems Business Overview
11.18.3 REVIVO BioSystems Organ On Chip Introduction
11.18.4 REVIVO BioSystems Revenue in Organ On Chip Business (2021–2026)
11.18.5 REVIVO BioSystems Recent Development
11.19 MesoBioTech
11.19.1 MesoBioTech Company Details
11.19.2 MesoBioTech Business Overview
11.19.3 MesoBioTech Organ On Chip Introduction
11.19.4 MesoBioTech Revenue in Organ On Chip Business (2021–2026)
11.19.5 MesoBioTech Recent Development
11.20 Beijing Daxiang Biotech
11.20.1 Beijing Daxiang Biotech Company Details
11.20.2 Beijing Daxiang Biotech Business Overview
11.20.3 Beijing Daxiang Biotech Organ On Chip Introduction
11.20.4 Beijing Daxiang Biotech Revenue in Organ On Chip Business (2021–2026)
11.20.5 Beijing Daxiang Biotech Recent Development
11.21 AVATARGET
11.21.1 AVATARGET Company Details
11.21.2 AVATARGET Business Overview
11.21.3 AVATARGET Organ On Chip Introduction
11.21.4 AVATARGET Revenue in Organ On Chip Business (2021–2026)
11.21.5 AVATARGET Recent Development
11.22 Suzhou Jiyan Biopharmaceutical
11.22.1 Suzhou Jiyan Biopharmaceutical Company Details
11.22.2 Suzhou Jiyan Biopharmaceutical Business Overview
11.22.3 Suzhou Jiyan Biopharmaceutical Organ On Chip Introduction
11.22.4 Suzhou Jiyan Biopharmaceutical Revenue in Organ On Chip Business (2021–2026)
11.22.5 Suzhou Jiyan Biopharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer